Building a drugtarget network and its applications

Expert Opinion on Drug Discovery

Volumn 4, Issue 11, 2009, Pages 1177-1189

  Lee, Soyoung ^a   Park, Keunwan ^a   Kim, Dongsup ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Drug disease network; Drug target network; Network analysis; Network integration; Target identification

Indexed keywords

IMATINIB; NONSTEROID ANTIINFLAMMATORY AGENT;

COMPARATIVE STUDY; DATA BASE; DRUG EFFECT; DRUG IDENTIFICATION; DRUG RESEARCH; DRUG TARGETING; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 72949115326     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903322234     Document Type: Review

References (90)

1. Kuhn M, Campillos M, Gonzalez P, et al. Bork P. Large-scale prediction of drug-target relationships. FEBS Lett 2008;582(8):1283-1290
2. Yildirim MA, Goh KI, Cusick ME, et al. Drug-target network. Nat Biotechnol 2007;25(10):1119-1126
3. Yamanishi Y, Araki M, Gutteridge A, et al. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 2008;24(13):I232-I40
4. Vina D, Uriarte E, Orallo F, et al. Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. Molecular Pharmaceutics 2009;6(3):825-835
5. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4(11):682-690
6. Goh KI, Cusick ME, Valle D, et al. The human disease network. Proc Natl Acad Sci USA 2007;104(21):8685-8690
7. Campillos M, Kuhn M, Gavin AC, et al. Drug target identification using side-effect similarity. Science 2008;321(5886):263-266
8. Prado-Prado FJ, De La Vega OM, Uriarte E, et al. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorgan Med Chem 2009;17(2):569-575
9. Gonzalez-Diaz H, Prado-Prado FJ. Unified QSAR and network-based computational chemistry approach to antimicrobials, part 1: Multispecies activity models for antifungals. J Comput Chem 2008;29(4):656-667
10. Wang Y, Xiao J, Suzek TO, et al. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res 2009;37(Web Server issue):W623-33
11. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36(Database issue):D901-6
12. Seiler KP, George GA, Happ MP, et al. ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res 2008;36(Database issue):D351-9
13. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006;34(Database issue):D354-7
14. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28(1):235-242
15. Boeckmann B, Bairoch A, Apweiler R, et al. The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 2003;31(1):365-370
16. Chen X, Ji ZL, Chen YZ. TTD: therapeutic target database. Nucleic Acids Res 2002;30(1):412-415
17. Chen L, Oughtred R, Berman HM, Westbrook J. TargetDB: a target registration database for structural genomics projects. Bioinformatics 2004;20(16):2860-2862
18. Gao Z, Li H, Zhang H, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008;9:104
19. Gunther S, Kuhn M, Dunkel M, et al. SuperTarget and matador: resources for exploring drug-target relationships. Nucleic Acids Res 2008;36(Database issue):D919-22
20. Hanzlik RP, Koen YM, Theertham B, et al. The reactive metabolite target protein database (TPDB)-a web-accessible resource. BMC Bioinformatics 2007;8:95
21. Zhang JX, Huang WJ, Zeng JH, et al. DITOP: drug-induced toxicity related protein database. Bioinformatics 2007;23(13):1710-1712
22. Ji ZL, Han LY, Yap CW, et al. Drug Adverse Reaction Target Database (DART): proteins related to adverse drug reactions. Drug Saf 2003;26(10):685-690
23. Database Mt. http://www.symyx.com. MDL information Systems, Inc. 2003
24. Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313(5795):1929-1935
25. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002;30(1):207-210
26. Parkinson H, Kapushesky M, Shojatalab M, et al. ArrayExpress-a public database of microarray experiments and gene expression profiles. Nucleic Acids Res 2007;35(Database issue):D747-50
27. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24(3):236-244 (Pubitemid 30132190)
28. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6(10):813-823
29. Amberger J, Bocchini CA, Scott AF, Hamosh A. McKusick's Online Mendelian Inheritance in Man (OMIM). Nucleic Acids Res 2009;37(Database issue):D793-6
30. Kuhn M, Mering C, Campillos M, et al. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res 2008;36(Database issue):D684-8
31. NIMH. http://pdsp.med.unc.edu. NIMH
32. Liu T, Lin Y, Wen X, et al. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007;35(Database issue):D198-201
33. Stark C, Breitkreutz BJ, Reguly T, et al. BioGRID: a general repository for interaction datasets. Nucleic Acids Research 2006;34:D535-D9
34. Caspi R, Foerster H, Fulcher CA, et al. MetaCyc: a multiorganism database of metabolic pathways and enzymes. Nucleic Acids Res 2006;34(Database issue):D511-6
35. Paolini GV, Shapland RH, Van Hoorn WP, et al. Global mapping of pharmacological space. Nat Biotechnol 2006;24(7):805-815
36. Keiser MJ, Roth BL, Armbruster BN, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007;25(2):197-206
37. Cases M, Mestres J. A chemogenomic approach to drug discovery: focus on cardiovascular diseases. Drug Discov Today 2009;14(9-10):479-485
38. Nagamine N, Sakakibara Y. Statistical prediction of protein chemical interactions based on chemical structure and mass spectrometry data. Bioinformatics 2007;23(15):2004-2012
39. Nagamine N, Shirakawa T, Minato Y, et al. Integrating statistical predictions and experimental verifications for enhancing protein-chemical interaction predictions in virtual screening. PLoS Comput Biol 2009;5(6):e1000397
40. Xie L, Li J, Xie L, Bourne PE. Drug Discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP Inhibitors. PLoS Comput Biol 2009;5(5):e1000387
41. Dunkel M, Gunther S, Ahmed J, et al. SuperPred: drug classification and target prediction. Nucleic Acids Res 2008;36(Web Server issue):W55-9
42. Li Q, Lai L. Prediction of potential drug targets based on simple sequence properties. BMC Bioinformatics 2007;8:353
43. Nacher JC, Schwartz JM. A global view of drug-therapy interactions. BMC Pharmacol 2008;8:5
44. Braun P, Tasan M, Dreze M, et al. An experimentally derived confidence score for binary protein-protein interactions. Nat Methods 2009;6(1):91-98
45. Bandyopadhyay S, Sharan R, Ideker T. Systematic identification of functional orthologs based on protein network comparison. Genome Res 2006;16(3):428-435
46. Berg J, Lassig M. Local graph alignment and motif search in biological networks. Proc Natl Acad Sci USA 2004;101(41):14689-14694
47. Dutkowski J, Tiuryn J. Identification of functional modules from conserved ancestral protein-protein interactions. Bioinformatics 2007;23(13):I149-I58
48. Guo X, Hartemink AJ. Domain-oriented edge-based alignment of protein interaction networks. Bioinformatics 2009;25(12):I240-I6
49. Kelley BP, Sharan R, Karp RM, et al. Conserved pathways within bacteria and yeast as revealed by global protein network alignment. Proc Natl Acad Sci USA 2003;100(20):11394-11399
50. Li YL, De Ridder D, De Groot MJL, Reinders MJT. Metabolic pathway alignment between species using a comprehensive and flexible similarity measure. Bmc Systems Biology 2008;2:111
51. Matthews LR, Vaglio P, Reboul J, et al. Identification of potential interaction networks using sequence-based searches for conserved protein-protein interactions or "interologs". Genome Res 2001;11(12):2120-2126
52. Ogata H, Fujibuchi W, Goto S, Kanehisa M. A heuristic graph comparison algorithm and its application to detect functionally related enzyme clusters. Nucleic Acids Res 2000;28(20):4021-4028
53. Sharan R, Ideker T. Modeling cellular machinery through biological network comparison. Nat Biotechnol 2006;24(4):427-433
54. Sharan R, Suthram S, Kelley RM, et al. Conserved patterns of protein interaction in multiple species. Proc Natl Acad Sci USA 2005;102(6):1974-1979
55. Stuart JM, Segal E, Koller D, Kim SK. A gene-coexpression network for global discovery of conserved genetic modules. Science 2003;302(5643):249-255
56. Yu HY, Luscombe NM, Lu HX, et al. Annotation transfer between genomes: protein-protein interologs and protein-DNA regulogs. Genome Res 2004;14(6):1107-1118
57. Bandyopadhyay S, Sharan R, Ideker T. Systematic identification of functional orthologs based on protein network comparison. Genome Res 2006;16(3):428-435
58. Koyuturk M, Grama A, Szpankowski W. An efficient algorithm for detecting frequent subgraphs in biological networks. Bioinformatics 2004;20(Suppl 1):i200-7
59. Frantz S. Playing dirty. Nature 2005;437(7061):942-943
60. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3(4):353-359
61. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005;26(4):178-182
62. Espinoza-Fonseca LM. The benefits of the multi-target approach in drug design and discovery. Bioorg Med Chem 2006;14(4):896-897
63. Hampton T. "Promiscuous" anticancer drugs that hit multiple targets may thwart resistance. Jama-J Am Med Assoc 2004;292(4):419
64. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006 Feb;16(1):127-136
65. Mencher SK, Wang LG. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol 2005;5(1):3
66. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004;9(15):641-651
67. Park K, Lee S, Ahn HS, Kim D. Predicting the multi-modal binding propensity of small molecules: towards an understanding of drug promiscuity. Mol Biosyst 2009;5(8):844-853
68. Wermuth CG. Multitargeted drugs: the end of the "one-target-one- disease" philosophy? Drug Discov Today 2004;9(19):826-827
69. Shoemaker BA, Panchenko AR. Deciphering protein-protein interactions. Part I. Experimental techniques and databases. PLoS Comput Biol 2007;3(3):e42
70. Engelen S, Trojan LA, Sacquin-Mora S, et al. Joint evolutionary trees: a large-scale method to predict protein interfaces based on sequence sampling. PLoS Comput Biol 2009;5(1)
71. Shoemaker BA, Panchenko AR. Deciphering protein-protein interactions. Part II. Computational methods to predict protein and domain interaction partners. PLoS Comput Biol 2007;3(4):e43
72. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007;12(1-2):34-42
73. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005;4(1):71-U10
74. Yeh P, Tschumi AI, Kishony R. Functional classification of drugs by properties of their pairwise interactions. Nat Genet 2006;38(4):489-494
75. Lehar J, Zimmermann GR, Krueger AS, et al. Chemical combination effects predict connectivity in biological systems. Mol Sys Biol 2007;3:80
76. Lehar J, Krueger AS, Avery W, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity (vol 7, pg 659, 2009). Nat Biotechnol 2009;27(7):1
77. Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003;100(13):7977-7982
78. Segre D, DeLuna A, Church GM, Kishony R. Modular epistasis in yeast metabolism. Nat Genet 2005;37(1):77-83
79. Araujo RP, Petricoin EF, Liotta LA. A mathematical model of combination therapy using the EGFR signaling network. Biosystems 2005;80(1):57-69
80. Young DW, Bender A, Hoyt J, et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol 2008;4(1):59-68
81. Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic inflammation in humans. Nature 2005;437(7061):1032-1037
82. Tanay A, Sharan R, Kupiec M, Shamir R. Revealing modularity and organization in the yeast molecular network by integrated analysis of highly heterogeneous genomewide data. Proc Natl Acad Sci USA 2004;101(9):2981-2986
83. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006;2(9):458-466
84. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3(8):673-683
85. Banks E, Nabieva E, Chazelle B, Singh M. Organization of physical interactomes as uncovered by network schemas. PLoS Comput Biol 2008;4(10)
86. Kashtan N, Alon U. Spontaneous evolution of modularity and network motifs. Proc Natl Acad Sci USA 2005;102(39):13773-13778
87. Ravasz E, Somera AL, Mongru DA, et al. Hierarchical organization of modularity in metabolic networks. Science 2002;297(5586):1551-1555
88. Royer L, Reimann M, Andreopoulos B, Schroeder M. Unraveling protein networks with power graph analysis. PLoS Comput Biol 2008;4(7)
89. Han S, Kim D. Inference of protein complex activities from chemical-genetic profile and its applications: predicting drug-target pathways. PLoS Comput Biol 2008;4(8):e1000162
90. Gerstein MB, Bruce C, Rozowsky JS, et al. What is a gene, post-ENCODE? History and updated definition. Genome Res 2007;17(6):669-681